B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma

Volume: 11, Issue: 9, Pages: 801 - 811
Published: Jun 1, 2019
Abstract
Multiple myeloma affects 30,000 new patients in the USA yearly, with 5-year median overall survival rates of 82, 62 and 40% for patients in groups I, II and III of the revised international staging system. Novel therapeutic and prognostic tools are changing the way we treat patients with this historically difficult to manage condition. B-cell maturation antigen (BCMA) represents an ideal therapeutic target in myeloma because of its high...
Paper Details
Title
B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma
Published Date
Jun 1, 2019
Volume
11
Issue
9
Pages
801 - 811
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.